Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 33.56 is 75% above its 5-year average of 19.22, around the middle of its 5-year range (4.08–56.10).
As of the fiscal period ended Tuesday, June 30, 2026. 27.36% below its 12-month average of 46.20.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 33.56.
QUICK RATIO (ACID-TEST)
33.56
QUICK RATIO (ACID-TEST) AVG TTM
46.20
QUICK RATIO (ACID-TEST) AVG 3Y
23.86
QUICK RATIO (ACID-TEST) AVG 5Y
19.22
QUICK RATIO (ACID-TEST) AVG 10Y
19.17
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-27.36%
CURRENT VS 3Y AVG
+40.63%
CURRENT VS 5Y AVG
+74.61%
CURRENT VS 10Y AVG
+75.01%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+901.68%
vs the sector median at left
Monopar Therapeutics Inc.
Market Cap
$533.04M
Quick Ratio (Acid-Test)
33.56
TTM Avg
46.20
3Y Avg
23.86
5Y Avg
19.22
Market Cap
$531.98M
Quick Ratio (Acid-Test)
8.95
TTM Avg
10.43
3Y Avg
5.97
5Y Avg
5.34
Market Cap
$531.52M
Quick Ratio (Acid-Test)
1.68
TTM Avg
2.23
3Y Avg
2.63
5Y Avg
2.59
Market Cap
$529.58M
Quick Ratio (Acid-Test)
27.59
TTM Avg
10.29
3Y Avg
10.12
5Y Avg
12.12
Market Cap
$538.01M
Quick Ratio (Acid-Test)
8.36
TTM Avg
10.03
3Y Avg
20.35
5Y Avg
14.11
Market Cap
$524.43M
Quick Ratio (Acid-Test)
25.13
TTM Avg
6.17
3Y Avg
7.34
5Y Avg
19.91
Market Cap
$519.25M
Quick Ratio (Acid-Test)
26.78
TTM Avg
15.83
3Y Avg
15.06
5Y Avg
15.09
Market Cap
$548.51M
Quick Ratio (Acid-Test)
1.87
TTM Avg
2.92
3Y Avg
5.55
5Y Avg
6.22
Market Cap
$516.76M
Quick Ratio (Acid-Test)
3.46
TTM Avg
4.63
3Y Avg
6.00
5Y Avg
6.13
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $533.04M | 33.56 | 46.20 | 23.86 | 19.22 |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 8.95 | 10.43 | 5.97 | 5.34 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | 1.68 | 2.23 | 2.63 | 2.59 |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | 27.59 | 10.29 | 10.12 | 12.12 |
| ProKidney Corp. (PROK)vs › | $538.01M | 8.36 | 10.03 | 20.35 | 14.11 |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | 25.13 | 6.17 | 7.34 | 19.91 |
| Altimmune, Inc. (ALT)vs › | $519.25M | 26.78 | 15.83 | 15.06 | 15.09 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | 1.87 | 2.92 | 5.55 | 6.22 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | 3.46 | 4.63 | 6.00 | 6.13 |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | 9.36 | 2.17 | 1.76 | 2.63 |
Quick Ratio
33.56
Excludes inventory
Current Ratio
33.56
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 33.56 |
| 2026-03-31 | 56.04 |
| 2025-12-31 | 51.35 |
| 2025-09-30 | 56.10 |
| 2025-06-30 | 33.94 |
| 2025-03-31 | 36.92 |
| 2024-12-31 | 11.47 |
| 2024-09-30 | 5.41 |
| 2024-06-30 | 6.59 |
| 2024-03-31 | 6.21 |
| 2023-12-31 | 4.17 |
| 2023-09-30 | 4.32 |
| 2023-06-30 | 4.12 |
| 2023-03-31 | 4.08 |
| 2022-12-31 | 4.21 |
| 2022-09-30 | 7.51 |
| 2022-06-30 | 7.61 |
| 2022-03-31 | 16.77 |
| 2021-12-31 | 12.98 |
| 2021-09-30 | 18.10 |
| 2021-06-30 | 22.10 |
| 2021-03-31 | 32.05 |
| 2020-12-31 | 14.28 |
| 2020-09-30 | 29.66 |
| 2020-06-30 | 22.21 |
| 2020-03-31 | 28.67 |
| 2019-12-31 | 18.27 |
| 2019-09-30 | 10.56 |
| 2019-06-30 | 11.95 |
| 2019-03-31 | 10.96 |
| 2018-12-31 | 18.32 |
| 2018-09-30 | 25.29 |
| 2018-06-30 | 23.67 |
| 2018-03-31 | 28.73 |
| 2017-12-31 | 29.28 |
| 2017-09-30 | 28.99 |
| 2017-06-30 | 17.20 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 32.48 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
